Dexdor: a new hospital-only sedative

Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY
Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY

Dexdor (dexmedetomidine) is licensed for adult patients in intensive care who require sedation not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Dexmedetomidine is a selective alpha-2 receptor agonist. It exerts its sedative effect through decreased firing of the locus coeruleus, the predominant noradrenergic nucleus in the brainstem. Dexmedetomidine has minimal respiratory depressive effects.

Dexdor must be given by intravenous infusion using a controlled infusion device.

View Dexdor drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

MIMS supplement on asthma and COPD

MIMS supplement on asthma and COPD

The June issue of MIMS includes a special supplement...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New antiviral treatment cuts COVID-19 mortality

New antiviral treatment cuts COVID-19 mortality

A combination of two monoclonal antibodies significantly...